AbbVie (NYSE: ABBV) reported Q2 EPS of $3.11, $0.03 better than the analyst estimate of $3.08. Revenue for the quarter came in at $13.96 billion versus the consensus estimate of $13.61 billion.
GUIDANCE:
AbbVie sees FY2021 EPS of $12.52-$12.62, versus the consensus of $12.60.
- AbbVie is updating its GAAP diluted EPS guidance for the full-year 2021 from $7.27 to $7.47 to $6.04 to $6.14. AbbVie is raising its adjusted diluted EPS for the full-year 2021 from $12.37 to $12.57 to $12.52 to $12.62. The company's 2021 adjusted diluted EPS guidance excludes $6.48 per share of intangible asset amortization expense, non-cash charges for contingent consideration adjustments and other specified items.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.